Study on the significance of sarcopenia as a risk of all deaths and cardiovascular disease in patients with type 2 diabetes

Not Applicable

• Conditions: Type 2 diabetes

• Registration Number: JPRN-UMIN000035538
• Lead Sponsor: ational Hospital Organization Kyoto Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-01-15
• Last Update Posted: 17 October 2023
• Study Completion: 2028-03-31

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 306

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who fall under any of the following criteria. (1) Patients with AST or ALT above 100 U/L (2) Patients with Cre above 3.0 mg/dL (3) Female patients who are suspected of being pregnant or pregnant (4) Patients with previous history of angioplasty and bypass surgery, history of hospitalization for heart failure treatment within the past one year (5) Patients with cancer with a history or treatment within five years (6) Patients taking corticosteroids (7) Patients with defects in their limbs (8) Patients wearing pacemakers (9) Patients judged by the investigator/project leader to be ineligible for other reasons

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Occurrence of any of all deaths and a composite of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, transient ischemic attacks, heart failure, hospitalization for unstable angina, implementation of angioplasty for coronary, carotid, cerebrovascular or peripheral artery)

Secondary Outcome Measures

Name	Time	Method
* All deaths * 4P-MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina) * Progression of microangiopathy (diabetic retinopathy, nephropathy) * Arteriosclerosis Index (CAVI)